* Laquinimod -- new data presented at ECTRIMS
* 57-57 -- exploratory clinical trial in progress
* RhuDex(TM) -- clinical development to continue following feedback
from UK MHRA
* ANYARA -- complete Phase I data published
* TASQ -- complete Phase I data published
* ISI -- project proceeding according to plan
* Net sales of SEK 7.7 M (8.8)
* Operating loss of SEK 164.6 M (loss: 167.0)
* Loss after tax of SEK 165.1 M (loss: 162.0)
* Loss per share for the period amounted to SEK 2.90 (loss: 3.30)
* Number of shares at the end of the period, thousands (incl.
warrants): 64,943
For further information, please contact:
Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95
Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54
Hans Kolam
CFO
Tel: +46 (0)46-19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
This report is also available at www.activebiotech.com
